Revenue from anti-CD20 therapeutic programs — Revenue
Biogen Revenue from anti-CD20 therapeutic programs — Revenue remained flat by 0.0% to $465.15M in Q4 2025 compared to the prior quarter. Year-over-year, this metric grew by 6.3%, from $437.48M to $465.15M. Over 4 years (FY 2021 to FY 2025), Revenue from anti-CD20 therapeutic programs — Revenue shows an upward trend with a 2.9% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Rising revenue signals successful commercialization and market share capture in the anti-CD20 space, whereas falling revenue may signal patent expirations, biosimilar competition, or shifts in clinical treatment standards.
Detailed definition
This metric measures the net revenue recognized from the sale of anti-CD20 therapeutic products, reflecting the company'...
Peer comparison
Similar to product-specific revenue reporting for specialized biologics or targeted immunotherapy segments at peer pharmaceutical firms.
biib_segment_revenue_from_anti_cd20_therapeutic_programs_revenueHistorical Data
| FY'21 | FY'22 | FY'23 | FY'24 | FY'25 | |
|---|---|---|---|---|---|
| Value | $1.66B | $1.70B | $1.69B | $1.75B | $1.86B |
| YoY Change | — | +2.5% | -0.6% | +3.6% | +6.3% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Biogen's revenue from anti-cd20 therapeutic programs — revenue?
- Biogen (BIIB) reported revenue from anti-cd20 therapeutic programs — revenue of $465.15M in Q4 2025.
- How has Biogen's revenue from anti-cd20 therapeutic programs — revenue changed year-over-year?
- Biogen's revenue from anti-cd20 therapeutic programs — revenue increased by 6.3% year-over-year, from $437.48M to $465.15M.
- What is the long-term trend for Biogen's revenue from anti-cd20 therapeutic programs — revenue?
- Over 4 years (2021 to 2025), Biogen's revenue from anti-cd20 therapeutic programs — revenue has grown at a 2.9% compound annual growth rate (CAGR), from $1.66B to $1.86B.
- What does revenue from anti-cd20 therapeutic programs — revenue mean?
- The revenue recognized from the company's anti-CD20 therapeutic product offerings.